H

Hospital General Universitario de Elche | Infectious Diseases Unit

Research site
(Unclaimed)
Location
CAMINO DE LA ALMAZARA 11 BAJO, Elche, Alicante, Spain
Site insights

Top conditions

Breast Cancer (18 trials)

Lung Cancer (12 trials)

Alzheimer Disease (11 trials)

Colorectal Cancer (11 trials)

Non-Small-Cell Lung Carcinoma (8 trials)

Top treatments

Carboplatin
Gemcitabine
Pembrolizumab
Irinotecan
Panitumumab
Palbociclib
Capecitabine
Bapineuzumab
Enzalutamide
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

34 of 154
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease....

Enrolling
Parkinson Disease
Drug: Placebo
Drug: Pirepemat

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib
Locations recently updated

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor...

Active, not recruiting
Breast Neoplasms
Drug: Abemaciclib
Drug: Placebo
Locations recently updated

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the t...

Enrolling
Metastatic Colorectal Cancer
Biological: Pembrolizumab
Biological: Cetuximab

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Enrolling
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immu...

Active, not recruiting
Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Biological: NM21-1480

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Enrolling
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in c...

Active, not recruiting
HER2+/HR+ Breast Cancer
Drug: ZW25 (Zanidatamab)
Drug: Palbociclib

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discont...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-d...

Active, not recruiting
Gastro-enteropancreatic Neuroendocrine Tumor
Drug: Lanreotide ATG
Drug: CAM2029

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting
Osteoarthritis
Drug: RTX-GRT7039
Drug: Placebo

This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to e...

Active, not recruiting
Parkinson Disease
Drug: Opicapone
Drug: L-DOPA/DDCI

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting
Parkinson's Disease (PD)
Drug: ABBV-951

Trial sponsors

Pfizer logo

Pfizer (13 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems